Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells.
Ansuvimab blocks binding between the Ebola virus glycoprotein (GP) and the Niemann-Pick C1 receptor by binding to the LEIKKPDGS epitope located in the receptor binding site of the GP1 subunit of GP[1].
Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) against GP-transfected target cells, with maximal activity at the concentration of 0.03 μg/mL[2].
Ansuvimab results in all macaques surviving after exposure to a lethal dose of Ebola virus in on day 0[1].
References:
[1]. Lee A, et, al. Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598.
[2]. Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351(6279):1339-42.